Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analysts give Enliven Therapeutics an average rating of Moderate Buy (five buys, one sell) with a 12‑month consensus price target of $43.40, though firm views diverge (HC Wainwright raised its target to $56 while Wall Street Zen and Weiss maintained sell calls).
• Shares opened at $41.20 (market cap ~$2.51B) and trade above the 50‑day ($36.81) and 200‑day ($27.20) moving averages, but the company missed quarterly EPS at ($0.48) vs. ($0.42) expected and analysts forecast ~‑1.7 EPS for the year.
• Insiders have been selling recently—CFO Benjamin Hohl sold 10,000 shares and insiders sold 16,230 shares (~$473k) in the last three months—though insiders still own about 25.90% of the stock.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $43.40.

ELVN has been the topic of several research reports. Wall Street Zen cut Enliven Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday. HC Wainwright raised their price target on Enliven Therapeutics from $48.00 to $56.00 and gave the company a "buy" rating in a report on Thursday, March 26th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. Finally, Mizuho increased their target price on Enliven Therapeutics from $41.00 to $45.00 and gave the company an "outperform" rating in a research report on Wednesday, March 25th.

Enliven Therapeutics Stock Performance

Shares of NASDAQ:ELVN opened at $41.20 on Thursday. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of -22.15 and a beta of 0.32. The firm has a fifty day moving average price of $36.81 and a 200 day moving average price of $27.20. Enliven Therapeutics has a fifty-two week low of $14.78 and a fifty-two week high of $48.53.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.06). As a group, research analysts predict that Enliven Therapeutics will post -1.7 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Benjamin Hohl sold 10,000 shares of the business's stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $29.58, for a total value of $295,800.00. Following the sale, the chief financial officer directly owned 51,000 shares in the company, valued at $1,508,580. The trade was a 16.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Richard A. Heyman sold 1,230 shares of the company's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total transaction of $32,201.40. Following the sale, the director owned 22,647 shares in the company, valued at $592,898.46. This represents a 5.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 16,230 shares of company stock valued at $473,201 in the last three months. Corporate insiders own 25.90% of the company's stock.

Hedge Funds Weigh In On Enliven Therapeutics

Large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. lifted its position in Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company's stock worth $44,000 after buying an additional 594 shares during the last quarter. BNP Paribas Financial Markets increased its position in Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock valued at $75,000 after acquiring an additional 930 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Enliven Therapeutics in the fourth quarter valued at $83,000. Quantbot Technologies LP lifted its holdings in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock worth $90,000 after acquiring an additional 1,434 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Enliven Therapeutics during the 4th quarter worth about $95,000. Institutional investors own 95.08% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.